Hence, the differential cell survival observed between ALK+ and ALK- cell lines upon combination drug treatment is dependent on ERBB and ALK activities which are critical only in the EML4-ALK-driven NSCLC cell lines. This evidence concerns the gene EGFR and non-small cell lung carcinoma.